Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Ipazilide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PTGIR | P43119 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipazilide SCHEMBL120490 | 1.00 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| Ipazilide SCHEMBL635854 | 0.95 | MAPK1 (0.55) | MAPK1KMT2AMEN1TP53GAA | |
| Ipazilide SCHEMBL9877353 | 0.94 | MAPK1 (0.54) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL10358746 | 0.91 | TP53 (0.52) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9877376 | 0.90 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9878032 | 0.90 | MAPK1 (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9877916 | 0.89 | MAPK1 (0.50) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL10556849 | 0.89 | MAPK1 (0.50) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9878705 | 0.89 | POLB (0.51) | MAPK1KMT2AMEN1TP53GAA | |
| SCHEMBL9876977 | 0.88 | MEN1 (0.52) | MAPK1KMT2AMEN1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2024-07-25 | — | — | US | disclosed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3258958-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-05-26 | — | — | EP | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3692989-A1 | USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS | Afecta Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA | 2020-06-25 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-2000050020-A2 | USE OF SULFAMATE DERIVATIVES FOR TREATING IMPULSE CONTROL DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-4988725-A | Cardiovascular disorders, antiarrhythmia agents | STERLING DRUG INC. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0392160-A1 | Azole-1-alkanamides as antiarrhythmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-10-17 | — | — | EP | disclosed |
| US-4962120-A | ANTIARRHYTHMIA AGENTS | STERLING DRUG INC. (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0388654-A2 | Azole-1-alkanamides as antiarrhythmic agents and preparation thereof | STERLING DRUG INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4916150-A | 1H-pyrazole-1-alkanamines antiarrhythmic compositions and use | STERLING DRUG INC. (US) | 1990-04-10 | — | — | US | disclosed |
| US-4898880-A | N-(heterocycle)alkyl)-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use | STERLING DRUG INC. (US) | 1990-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | KMT2A 1923/4885MEN1 4859/4885MAPK1 3892/4885 |
| US-20240247313-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KMT2A 1923/4885MEN1 4859/4885MAPK1 3892/4885 |
| US-20200199679-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KMT2A 1923/4885MEN1 4859/4885MAPK1 3892/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | KMT2A 3261/4885MEN1 3479/4885MAPK1 4289/4885 |
| US-10995374-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | KMT2A 1923/4885MEN1 4859/4885MAPK1 3892/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | KMT2A 1923/4885MEN1 4859/4885MAPK1 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.